At a glance
ClinicalIndex Comparison RecordN/ACompleted· 20 enrolled
Drug / intervention
Minocyclinedrug
Likely dose
Minocycline 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Add-on Pilot Trial of Minocycline in Fragile X Syndrome
In Brief
A clinical study evaluating Minocycline for Fragile X Syndrome. Completed, enrolled 20 participants across 1 site.
Detailed Summary
Fragile X Syndrome (FXS) is the most common known inherited form of mental impairment, developmental disability and autism. Minocycline is an antibiotic that has recently been used to treat the mouse model for Fragile X, and was found to reverse the structural abnormalities that are seen their brain cells. The purpose of this research study is to determine if minocycline is an effective treatment for patients with fragile X syndrome (FXS).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFragile X Syndrome
CountriesCanada
CollaboratorsFragile X Research Foundation of Canada
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2007
Primary CompletionNov 2008
Study CompletionJan 2009
First PostedMar 2009
TodayJul 2026
First PostedMar 10, 2009
Enrollment StartOct 1, 2007
Primary CompletionNov 1, 2008
Study CompletionJan 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 17.3 years ago
Interventions
Minocyclinedrug
50-100 mg PO BID for 8 weeks with an option for a 1 year extension.